Trial
NCT00480025
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Lung Cancer, Non-Small Cell
Intervention
GSK1572932A Antigen-Specific Cancer Immunotherapeutic
Why stopped
The study was terminated following assessment of the lack of efficacy of the study product by the Independent Data monitoring Committee for the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-12-22